Ferric citrate: cardio- and renoprotective in chronic kidney disease?

Abstract

Ferric citrate is a phosphate binder that may also be used to treat iron-deficiency anemia. In human studies, ferric citrate treatment in the setting of chronic kidney disease has been associated with effective phosphate control, improved iron and hematologic parameters, and decreased fibroblast growth factor 23 levels. In the present study, mice with chronic kidney disease treated with ferric citrate have similarly improved biochemical profiles, but also have improved cardiac and renal function and prolonged survival.

• Authors: Mark R Hanudel
• Journal: Kidney international (Kidney Int) Vol. 96 Issue 6 Pg. 1277-1279 (12 2019) ISSN: 1523-1755 [Electronic] United States
• PMID: 31759486 (Publication Type: Journal Article, Comment)
• Copyright: Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Chemical References

• Ferric Compounds
• Fibroblast Growth Factors
• ferric citrate
• Fibroblast Growth Factor-23

Topics

• Anemia, Iron-Deficiency
• Animals
• Ferric Compounds
• Fibroblast Growth Factor-23
• Fibroblast Growth Factors
• Humans
• Mice
• Renal Insufficiency, Chronic